{"product_id":"zyduslife-swot-analysis","title":"Zydus Lifesciences SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eZydus Lifesciences boasts significant strengths in its robust R\u0026amp;D pipeline and expanding global footprint, but faces potential threats from intense market competition and regulatory changes. Understanding these internal capabilities and external pressures is crucial for strategic planning.\u003c\/p\u003e\n\u003cp\u003eWant the full story behind Zydus Lifesciences' strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZydus Lifesciences showcases a robust and diversified product portfolio, encompassing generics, branded formulations, biosimilars, and vaccines. This breadth ensures a stable and varied revenue stream, mitigating risks associated with over-reliance on any single therapeutic area or product.  For instance, in FY24, the company reported strong growth across its key segments, with generics and branded formulations forming the backbone of its sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Financial Performance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZydus Lifesciences showcased impressive financial health, with Q4 FY24 and Q1 FY25 reporting substantial revenue and net profit increases.  The company achieved a 13% revenue jump and a remarkable 97% net profit growth for the entirety of FY24.\u003c\/p\u003e\n\u003cp\u003eThis robust financial trajectory is further bolstered by expanding EBITDA margins, underscoring Zydus's enhanced operational efficiency and profitability in the recent fiscal periods.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust R\u0026amp;D Investments and Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZydus Lifesciences demonstrates a strong commitment to innovation through consistent, significant R\u0026amp;D investments, often allocating a substantial percentage of its revenue to this crucial area.  This dedication is evident in its robust pipeline, which features a focus on novel chemical entities, advanced biologics, and critical vaccines.\u003c\/p\u003e\n\u003cp\u003eThis strategic R\u0026amp;D focus has yielded tangible results, including recent approvals from the US Food and Drug Administration (USFDA) for several key drugs, underscoring the effectiveness of their research endeavors.  The company's objective is to cultivate a portfolio of differentiated, high-value pharmaceutical products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Presence and Manufacturing Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZydus Lifesciences boasts a formidable global manufacturing presence, operating more than 30 production facilities strategically located across India, Brazil, and the USA. This extensive network is crucial for optimizing its supply chain and effectively supporting its ambitious international market expansion plans.\u003c\/p\u003e\n\u003cp\u003eThe company's robust manufacturing capabilities are a key strength, allowing for efficient production and distribution of its pharmaceutical products worldwide. This global footprint is instrumental in Zydus's strategy to penetrate and grow in vital markets, including the significant US pharmaceutical sector, as well as various other emerging economies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Manufacturing Footprint:\u003c\/strong\u003e Operates over 30 manufacturing plants in India, Brazil, and the USA.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSupply Chain Efficiency:\u003c\/strong\u003e Facilitates streamlined logistics and cost-effective operations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Expansion Support:\u003c\/strong\u003e Enables the company to effectively serve and grow in international markets, particularly the US and emerging economies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Acquisitions and Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZydus Lifesciences has bolstered its capabilities through strategic acquisitions and partnerships. A notable example is its 50% stake in Sterling Biotech, focusing on animal-free protein production, which positions Zydus in a growing segment of the biotechnology market. This aligns with their strategy to tap into new revenue streams and expand their product portfolio in specialized biotech areas.\u003c\/p\u003e\n\u003cp\u003eFurther demonstrating this strategic approach, Zydus acquired Agenus' US biologics manufacturing facilities. This move is crucial for expanding into the biologics Contract Development and Manufacturing Organization (CDMO) space, a high-growth area in the pharmaceutical industry. Such acquisitions are key to enhancing their manufacturing capacity and offering integrated services to other biotech companies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eAcquisition of Sterling Biotech:\u003c\/strong\u003e Secured a 50% stake to enter the animal-free protein production market.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAcquisition of Agenus' US Biologics Facilities:\u003c\/strong\u003e Expanded into the biologics CDMO sector, enhancing manufacturing capabilities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Rationale:\u003c\/strong\u003e These moves are designed to diversify revenue streams and capitalize on emerging biotech trends.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Portfolio Fuels Strong Financial Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZydus Lifesciences' diversified product range, spanning generics, branded formulations, biosimilars, and vaccines, ensures a stable revenue base. This breadth reduces reliance on any single market segment, providing resilience. The company's strong financial performance in FY24, marked by a 13% revenue increase and a 97% net profit jump, highlights its operational strength and market penetration.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Zydus Lifesciences’s internal and external business factors, highlighting its strengths in R\u0026amp;D and market reach, while also identifying potential weaknesses in product diversification and external threats from regulatory changes and competition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a clear, actionable SWOT analysis for Zydus Lifesciences, simplifying complex strategic data into an easy-to-digest format for pain point resolution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMixed Stock Performance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZydus Lifesciences' stock performance presents a mixed bag. While it managed to outperform the Sensex over a three-month span, its performance over the last year has seen a significant downturn. This divergence in short-term versus long-term trends can create uncertainty for investors.\u003c\/p\u003e\n\u003cp\u003eFurther analysis of the company's moving averages reveals a somewhat volatile picture. This suggests that the stock's price action hasn't followed a consistently upward or downward trend, indicating potential market indecision. Such mixed signals can make investors hesitant, potentially impacting the stock's overall valuation and investor confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarginal Profit Drop in Q4 FY25 (vs Q4 FY24)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWhile Zydus Lifesciences demonstrated robust performance for the entirety of fiscal year 2025, the fourth quarter (Q4 FY25) saw a marginal decline in net profit when compared to the same period in the previous fiscal year (Q4 FY24). This dip, amounting to a slight percentage decrease, was largely influenced by the recognition of exceptional items, which are non-recurring financial events that can temporarily impact profitability.\u003c\/p\u003e\n\u003cp\u003eThese quarterly fluctuations, even when attributed to one-off factors, can introduce a degree of investor caution. For instance, if Q4 FY25 net profit was ₹600 crore compared to ₹620 crore in Q4 FY24, this represents a 3.2% drop, highlighting the impact of these exceptional items on short-term financial metrics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric Competition in Key Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZydus Lifesciences is bracing for intensified generic competition in key markets, particularly in the United States. For instance, the company anticipates increased pressure on products like Asacol, a significant contributor to its US revenue stream.\u003c\/p\u003e\n\u003cp\u003eThis heightened competition is a direct consequence of patent expirations and the entry of multiple generic manufacturers. Such an environment typically leads to substantial pricing erosion, which can directly impact Zydus's sales volume and profit margins for these affected products in the vital US market.\u003c\/p\u003e\n\u003cp\u003eFor the fiscal year ending March 31, 2024, Zydus Lifesciences reported consolidated revenue of approximately INR 17,000 crore. The US market represents a substantial portion of this revenue, making the impact of generic competition on key products a critical concern for future financial performance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on US Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eZydus Lifesciences' significant reliance on the United States market presents a notable weakness. In the fiscal year 2023, the US accounted for approximately 45% of the company's total revenue, highlighting its crucial role in Zydus's financial health.\u003c\/p\u003e\n\u003cp\u003eThis concentration exposes Zydus to considerable risks. Adverse regulatory shifts, intensified pricing pressures, and evolving healthcare policies within the US could disproportionately impact the company's financial performance. For instance, any major changes in the US FDA's approval processes or reimbursement policies could create substantial headwinds.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eUS Revenue Concentration:\u003c\/strong\u003e The US market represents a substantial portion of Zydus's consolidated revenues, estimated around 45% in FY23.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Sensitivity:\u003c\/strong\u003e Susceptibility to adverse regulatory changes and pricing pressures within the US healthcare system.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePolicy Impact:\u003c\/strong\u003e Vulnerability to evolving healthcare policies and reimbursement structures in the United States.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGeographic Risk:\u003c\/strong\u003e Over-dependence on a single major market amplifies the impact of any significant downturn or policy change in the US.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnalyst Concerns Post FY25\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAnalysts have voiced concerns about Zydus Lifesciences' US sales performance expectations following the 2025 fiscal year, with some brokerages expressing caution. This sentiment, particularly around current valuations, could temper investor enthusiasm and impact the stock's future growth. For instance, reports from early 2024 highlighted specific analyst ratings that factored in potential slowdowns in key US markets.\u003c\/p\u003e\n\u003cp\u003eThese expert opinions are critical as they directly influence investor perception and can create headwinds for the stock's valuation. A notable point of discussion among financial professionals in Q1 2024 revolved around the sustainability of Zydus's US market share against increasing competition. This suggests a need for the company to proactively communicate its long-term strategy and identify new avenues for expansion beyond the current fiscal year.\u003c\/p\u003e\n\u003cp\u003eThe company's ability to demonstrate robust, diversified growth drivers will be key to addressing these analyst concerns. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eUS Sales Trajectory:\u003c\/strong\u003e Brokerages have flagged potential deceleration in US sales post-FY25.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eValuation Wariness:\u003c\/strong\u003e Current stock valuations are a point of concern for some analysts.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInvestor Sentiment Impact:\u003c\/strong\u003e Analyst concerns can negatively affect investor confidence and stock performance.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNeed for Future Clarity:\u003c\/strong\u003e Zydus must articulate clear growth strategies beyond the immediate fiscal year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma Firm Grapples with US Market \u0026amp; Generic Competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZydus Lifesciences faces significant pressure from intensified generic competition in its key markets, particularly the United States. For instance, the company anticipates increased competition for its product Asacol, a substantial revenue generator in the US. This heightened competition, driven by patent expirations and the entry of multiple generic manufacturers, typically leads to considerable price erosion, directly impacting sales volumes and profit margins for affected products.\u003c\/p\u003e\n\u003cp\u003eThe company's substantial reliance on the US market, which accounted for approximately 45% of its total revenue in FY23, presents a notable weakness. This geographic concentration exposes Zydus to considerable risks, as adverse regulatory shifts, pricing pressures, and evolving healthcare policies in the US could disproportionately affect its financial performance.\u003c\/p\u003e\n\u003cp\u003eAnalysts have expressed concerns regarding Zydus Lifesciences' US sales performance trajectory beyond fiscal year 2025, with some brokerages indicating caution. This sentiment, coupled with wariness about current valuations, could dampen investor enthusiasm and negatively impact the stock's future growth prospects.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eZydus Lifesciences SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eYou're viewing a live preview of the actual Zydus Lifesciences SWOT analysis. The complete version becomes available after checkout, offering a comprehensive look at the company's Strengths, Weaknesses, Opportunities, and Threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610721141113,"sku":"zyduslife-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/zyduslife-swot-analysis.png?v=1754744766","url":"https:\/\/growthsharematrix.com\/products\/zyduslife-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}